The news roundup for the week ending 11 March 2016.
University College Cork and Enterprise Ireland-backed Gateway UCC sets up a new accelerator and welcomes the first cohort.
Cambridge University launches Enterprise Fund IV
University of Cambridge Enterprise Fund IV enables university alumni and investors to back companies emerging from Cambridge University.
Incanthera diagnoses $894,000 grant
The Bradford spinout will conduct a phase 1 clinical trial for a potential cancer treatment following a $894,000 cancer charity grant.
Atlas Genetics finds EU approval
Bath University spinout Atlas Genetics gains approval to sell its rapid chlamydia test within the EU.
Michigan revs up TechLab accelerator
TechLab at Mcity is set to bring together students, university researchers and transport startups to push forward development of driverless car technologies.
Newly launched spinout Z53 Therapeutics is working on cancer treatments that exploit a discovery of how to repair a protein that suppresses tumour formation.
Concordia spinout Wrnch has received cash from a consortium including commercialisation firm Aligo Innovation and TandemLaunch.
Visikol clears the way for $500,000
The Rutgers spinout obtains $500,000 for its biological clearing agent that enables the visualisation of biological specimens’ internal structures.
Imperial Innovations leads a funding round for Precision Ocular, while Consort Medical also participates and enters a collaboration agreement with the spinout.
Tech transfer award lights up Dresden
German Physical Society has given its Technology Transfer Award to Technical University of Dresden, its Institute for Applied Photophysics and spinout Novaled.
Immucor sequences Sirona acquisition
Stanford spinout Sirona Genomics produces technology to map and manage bloody type, organ and other genomic assessments more accurately in a database.
